These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 22890637)

  • 41. Is vasospasm actually bad for you?
    Crowley RW; Macdonald RL
    World Neurosurg; 2011; 76(1-2):6. PubMed ID: 21839927
    [No Abstract]   [Full Text] [Related]  

  • 42. Inflammasome Proteins in Cerebrospinal Fluid of Patients with Subarachnoid Hemorrhage are Biomarkers of Early Brain Injury and Functional Outcome.
    Wu Q; Wang XL; Yu Q; Pan H; Zhang XS; Zhang QR; Wang HD; Zhang X
    World Neurosurg; 2016 Oct; 94():472-479. PubMed ID: 27443226
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Attributing hypodensities on CT to angiographic vasospasm is not sensitive and unreliable.
    Ibrahim GM; Weidauer S; Vatter H; Raabe A; Macdonald RL
    Stroke; 2012 Jan; 43(1):109-12. PubMed ID: 21998061
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Unfavorable Outcome After Good Grade Aneurysmal Subarachnoid Hemorrhage: Exploratory Analysis.
    Eagles ME; Tso MK; Ayling OGS; Wong JH; MacDonald RL
    World Neurosurg; 2020 Dec; 144():e842-e848. PubMed ID: 32956894
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Factors Influencing Discontinuation of Clazosentan Therapy in Elderly Patients with Aneurysmal Subarachnoid Hemorrhage: A Retrospective Study from a Japanese Single Center.
    Mutoh T; Aono H; Seto W; Kimoto T; Tochinai R; Moroi J; Ishikawa T
    Med Sci Monit; 2024 Feb; 30():e943303. PubMed ID: 38361355
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Letter: Clinical Benefit of Clazosentan in Vasospasm After Subarachnoid Hemorrhage: Are We There Yet?
    Katiyar V; Kale A; Sharma R; Ganeshkumar A; Borkar SA
    Neurosurgery; 2023 Feb; 92(2):e37-e40. PubMed ID: 36637286
    [No Abstract]   [Full Text] [Related]  

  • 47. Challenges in collecting pharmacokinetic and pharmacodynamic information in an intensive care setting: PK/PD modelling of clazosentan in patients with aneurysmal subarachnoid haemorrhage.
    Zisowsky J; Fuseau E; Bruderer S; Krause A; Dingemanse J
    Eur J Clin Pharmacol; 2014 Apr; 70(4):409-19. PubMed ID: 24458541
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quantification of Cerebral Edema After Subarachnoid Hemorrhage.
    Choi HA; Bajgur SS; Jones WH; Savarraj JP; Ko SB; Edwards NJ; Chang TR; Hergenroeder GW; Dannenbaum MJ; Chen PR; Day AL; Kim DH; Lee K; Grotta JC
    Neurocrit Care; 2016 Aug; 25(1):64-70. PubMed ID: 26703130
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relationship of local infarctions to cognitive and psychosocial impairments after aneurysmal subarachnoid hemorrhage.
    Vilkki JS; Juvela S; Siironen J; Ilvonen T; Varis J; Porras M
    Neurosurgery; 2004 Oct; 55(4):790-802; discussion 802-3. PubMed ID: 15458587
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cerebral atrophy in patients on long-term regular hemodialysis treatment.
    Savazzi GM; Cusmano F; Degasperi T
    Clin Nephrol; 1985 Feb; 23(2):89-95. PubMed ID: 3872759
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High protein intake after subarachnoid hemorrhage improves oral intake and temporal muscle volume.
    Onodera H; Mogamiya T; Matsushima S; Sase T; Kawaguchi K; Nakamura H; Sakakibara Y
    Clin Nutr; 2021 Jun; 40(6):4187-4191. PubMed ID: 33622572
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term global and focal cerebral atrophy in perimesencephalic subarachnoid hemorrhage-a case-control study.
    Gama Lobo G; Fragata I
    Neuroradiology; 2022 Apr; 64(4):669-674. PubMed ID: 34495354
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Letter to the Editor. Clazosentan was superior to placebo, but was the comparison appropriate?
    Kimura T
    J Neurosurg; 2023 Mar; 139(1):299-300. PubMed ID: 36964737
    [No Abstract]   [Full Text] [Related]  

  • 54. Therapeutic time window for musicokinetic therapy in a persistent vegetative state after severe brain damage.
    Noda R; Maeda Y; Yoshino A
    Brain Inj; 2004 May; 18(5):509-15. PubMed ID: 15195797
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mouse cerebral magnetic resonance imaging fails to visualize brain volume changes after experimental subarachnoid hemorrhage.
    Atangana EN; Homburg D; Vajkoczy P; Schneider UC
    Acta Neurochir (Wien); 2015 Jan; 157(1):37-42. PubMed ID: 25398554
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Practical one-dimensional measurements of age-related brain atrophy are validated by 3-dimensional values and clinical outcomes: a retrospective study.
    Dunham CM; Cook AJ; Paparodis AM; Huang GS
    BMC Med Imaging; 2016 Apr; 16():32. PubMed ID: 27113039
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enlarged cerebrospinal fluid spaces in opiate-dependent male patients: a stereological CT study.
    Danos P; Van Roos D; Kasper S; Brömel T; Broich K; Krappel C; Solymosi L; Möller HJ
    Neuropsychobiology; 1998; 38(2):80-3. PubMed ID: 9732207
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Use of phenotropil in the treatment of asthenic syndrome and autonomic disturbances in the acute period of mild cranial brain trauma].
    Kalinskiĭ PP; Nazarov VV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(2):61-3. PubMed ID: 18689001
    [No Abstract]   [Full Text] [Related]  

  • 59. Stroke: disappointing results for clazosentan in CONSCIOUS-2.
    Meyers PM; Connolly ES
    Nat Rev Neurol; 2011 Oct; 7(12):660-1. PubMed ID: 22009282
    [No Abstract]   [Full Text] [Related]  

  • 60. [Atrophy cerebral muscles after brain injury].
    LECHNER H
    Arch Int Neurol; 1948; 67(8):172. PubMed ID: 18892866
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.